Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
Phase 2 in Austria and England
This is a Phase 2 open study to assess efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated locally advanced/metastatic squamous cell carcinoma (SCC).
Prof. Johann W. Bauer MD
Onconova Therapeutics, Inc.